Research programme: abuse-resistant analgesics - Acura Pharmaceuticals

Drug Profile

Research programme: abuse-resistant analgesics - Acura Pharmaceuticals

Alternative Names: acetaminophen/niacin/oxycodone; acetaminophen/oxycodone; acetaminophen/oxycodone/niacin; Acuracet; Acuracet with Niacin; niacin/acetaminophen/oxycodone; niacin/oxycodone/acetaminophen; niacin/oxycodone/paracetamol; niacin/paracetamol/oxycodone; oxycodone/acetaminophen; oxycodone/acetaminophen/niacin; oxycodone/niacin/acetaminophen; oxycodone/niacin/paracetamol; oxycodone/paracetamol; oxycodone/paracetamol/niacin; paracetamol/niacin/oxycodone; paracetamol/oxycodone; paracetamol/oxycodone/niacin

Latest Information Update: 03 Oct 2012

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Acura Pharmaceuticals
  • Class Acetanilides; Morphine derivatives; Small molecules
  • Mechanism of Action Opioid receptor agonists; Prostaglandin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Pain

Most Recent Events

  • 26 Sep 2012 Acura Pharmaceuticals announced a letter agreement with Pfizer providing for the termination of Pfizer's license to Acura's AVERSION Technology used in three developmental opioid products as of 26 September 2012 and the transfer of those products, one of which is oxycodone/paracetamol and another undisclosed opioid, back to Acura. This represents an earlier return of development products to Acura
  • 26 Jul 2012 Pfizer exercises its right to terminate its licence for oxycodone/paracetamol and another undisclosed opioid in Canada, Mexico, USA
  • 28 Mar 2012 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top